Edinburgh, UK, January 9, 2008: Ardana Plc (LSE:ARA), the emerging
pharmaceutical company specialising in improving human reproductive health,
today announces the positive outcome of a pre-Investigational New Drug (IND)
meeting with the United States Food and Drug Administration (FDA) for the
development of its lead compound Teverelix LA (long-acting) for the treatment of
endometriosis.
